Search results for "female genital diseases and pregnancy complications"

showing 10 items of 310 documents

Introduction

2014

The cellular, genetic, and hormonal understanding of uterine fibroids is rapidly growing, but the therapeutic options remain similar. Are we really advancing the field?

Reproductive MedicineUterine fibroidsbusiness.industrymedicineObstetrics and Gynecologymedicine.diseaseBioinformaticsbusinessfemale genital diseases and pregnancy complicationsFertility and Sterility
researchProduct

Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause

2013

Context: Polycystic ovary syndrome (PCOS) is diagnosed during the reproductive years when women present with 2 of 3 of the following criteria: 1) irregular menstrual cycles or anovulation, 2) hyperandrogenism, and 3) PCO morphology. However, there is evidence that PCOS can be identified from early infancy to puberty based on predisposing environmental influences. There is also increasing information about the PCOS phenotype after menopause. The goal of this review is to summarize current knowledge about the appearance of PCOS at different life stages and the influence of reproductive maturation and senescence on the PCOS phenotype. Evidence: PubMed, the bibliography from the Evidence-Based …

Senescencemedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryContext (language use)BiochemistrySettore MED/13 - EndocrinologiaAnovulationEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaInternal medicinemedicinePregnancybusiness.industryPolycystic ovary syndrome (PCOS)Biochemistry (medical)Hyperandrogenismnutritional and metabolic diseasesmedicine.diseasePolycystic ovaryPCOS Pregnancy infancy puberty menopause obesity AMH cardiovascular risk birth weightSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsMenopauseEndocrinologybusiness
researchProduct

Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations

2013

Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are associated with mutations in genes encoding proteins of complement system (aHUS). We describe two patients with a clinical history of STEC-HUS, who developed end-stage renal disease (ESRD) soon after disease onset. They received a kidney transplant but lost the graft for HUS recurrence, a complication more commonly observed in aHUS. Before planning a second renal transplantation, the two patients underwent genetic screening for aHUS-associat…

Shiga-toxinGraft RejectionMaleDNA Primer030232 urology & nephrologyEscherichia coli InfectionGene mutationurologic and male genital diseasesGastroenterology0302 clinical medicineRecurrenceRisk Factorshemic and lymphatic diseasesImmunology and AllergyPharmacology (medical)gene mutationKidney transplantationEscherichia coli Infections0303 health sciencesKidneymedicine.diagnostic_testShiga-Toxigenic Escherichia coliAntigens CD46Microangiopathic hemolytic anemiaMiddle AgedPrognosisfemale genital diseases and pregnancy complications3. Good healthPedigreemedicine.anatomical_structureComplement Factor IComplement factor I; gene mutation; hemolytic uremic syndrome; kidney transplantation; membrane cofactor protein; Shiga-toxin; Adult; Antigens CD46; Case-Control Studies; Complement Factor I; DNA Primers; Escherichia coli Infections; Female; Genetic Testing; Graft Rejection; Hemolytic-Uremic Syndrome; Heterozygote; Humans; Kidney Failure Chronic; Kidney Transplantation; Male; Middle Aged; Mutation; Pedigree; Prognosis; Recurrence; Risk Factors; Shiga-Toxigenic Escherichia coli; Thrombocytopenia; Young Adult; Transplantation; Immunology and Allergy; Pharmacology (medical)FemaleCase-Control StudieHumanAdultmedicine.medical_specialtyHeterozygotePrognosiComplement factor IMembrane Cofactor Protein03 medical and health sciencesYoung AdultInternal medicinemedicineHumansGenetic Testing030304 developmental biologyGenetic testingDNA PrimersTransplantationbusiness.industryCD46Risk Factormedicine.diseaseKidney TransplantationThrombocytopeniaTransplantationCase-Control StudiesImmunologyHemolytic-Uremic SyndromeMutationhemolytic uremic syndromeKidney Failure ChronicbusinessAmerican Journal of Transplantation
researchProduct

Extracorporeal Shock Wave Lithotripsy of Ureteral Stones: Clinical Experience and Experimental Findings

1986

AbstractESWL of impacted ureteral or caliceal stones is not as successful as expected. To study this problem a model for extracorporeal shock wave lithotripsy of ureteral stones has been designed. After initial fragmentation of the outer shell of impacted stones during the first series of shock wave application those fragments are kept in place by external mucosal contact, creating a lot of new interfaces.Absorption or reflection of shock wave energy within this fragmented shell seems to be responsible for the poor success rate in these cases. In regard to our experimental and clinical results we advise pushing ureteral stones back into the renal collecting system by means of a ureteral cat…

Shock wavemedicine.medical_specialtyUreteral Calculiurogenital systembusiness.industryUrologymedicine.medical_treatmentIn Vitro Techniquesurologic and male genital diseasesCollection systemExtracorporeal shock wave lithotripsyfemale genital diseases and pregnancy complicationsSurgeryModels StructuralKidney CalculiLithotripsymedicineHumansbusinessUrethral catheterJournal of Urology
researchProduct

Tetraspanin CD151 Mediates Papillomavirus Type 16 Endocytosis

2013

ABSTRACT Human papillomavirus type 16 (HPV16) is the primary etiologic agent for cervical cancer. The infectious entry of HPV16 into cells occurs via a so-far poorly characterized clathrin- and caveolin-independent endocytic pathway, which involves tetraspanin proteins and actin. In this study, we investigated the specific role of the tetraspanin CD151 in the early steps of HPV16 infection. We show that surface-bound HPV16 moves together with CD151 within the plane of the membrane before they cointernalize into endosomes. Depletion of endogenous CD151 did not affect binding of viral particles to cells but resulted in reduction of HPV16 endocytosis. HPV16 uptake is dependent on the C-termina…

Small interfering RNAEndosomevirusesmedia_common.quotation_subjectDNA Mutational AnalysisImmunologyEndocytic cycleIntegrinTetraspanin 24EndocytosisMicrobiologyClathrinCell LineTetraspaninVirologyHumansInternalizationmedia_commonHuman papillomavirus 16integumentary systembiologyvirus diseasesVirus InternalizationMolecular biologyEndocytosisfemale genital diseases and pregnancy complicationsVirus-Cell InteractionsCell biologyGene Knockdown TechniquesInsect Sciencebiology.proteinMutant ProteinsJournal of Virology
researchProduct

Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TR…

2016

5522Background: Sorafenib (S), a multi TK-inhibitor in combination with topotecan (T), a topoisomerase inhibitor showed preclinical synergistic effects in ovarian cancer but critical toxicity. To a...

SorafenibOncologyCancer Researchmedicine.medical_specialty030219 obstetrics & reproductive medicineendocrine system diseasesmedicine.drug_classbusiness.industryPlacebomedicine.diseasefemale genital diseases and pregnancy complicationsDouble blind03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineToxicitymedicineTopotecanbusinessOvarian cancerTopoisomerase inhibitormedicine.drugPlatinum resistantJournal of Clinical Oncology
researchProduct

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

2018

The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC. More recently, regorafenib and nivolumab have received approval in the second-line setting after sorafenib, with further positive phase 3 studies emerging in the first line (lenvatinib non-inferior to sorafenib) and second line versus placebo (cabozantinib and ramucirumab). A key recommendation in the management of patients receiving sorafenib is to promote close communication between the patient and the physician so that adverse events (AEs) are detected early and severe AEs can b…

SorafenibOncologyNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularCabozantinibAntineoplastic Agentsurologic and male genital diseasesRamucirumab03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineRegorafenibmedicineHumansheterocyclic compoundsRadiology Nuclear Medicine and imagingAdverse effectneoplasmsProtein Kinase InhibitorsRandomized Controlled Trials as TopicClinical Trials as Topicbusiness.industryPhenylurea CompoundsLiver NeoplasmsGeneral MedicineSorafenibmedicine.diseasefemale genital diseases and pregnancy complicationsdigestive system diseasesOncologychemistry030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyNivolumabLenvatinibbusinessmedicine.drugCancer treatment reviews
researchProduct

Combining split-and-merge and multi-seed region growing algorithms for uterine fibroid segmentation in MRgFUS treatments

2016

Uterine fibroids are benign tumors that can affect female patients during reproductive years. Magnetic resonance-guided focused ultrasound (MRgFUS) represents a noninvasive approach that uses thermal ablation principles to treat symptomatic fibroids. During traditional treatment planning, uterus, fibroids, and surrounding organs at risk must be manually marked on MR images by an operator. After treatment, an operator must segment, again manually, treated areas to evaluate the non-perfused volume (NPV) inside the fibroids. Both pre- and post-treatment procedures are time-consuming and operator-dependent. This paper presents a novel method, based on an advanced direct region detection model, …

SpeedupUterine fibroidsImage ProcessingBiomedical EngineeringThermal ablation02 engineering and technologyMagnetic Resonance Imaging InterventionalFocused ultrasound030218 nuclear medicine & medical imaging03 medical and health sciencesComputer-Assisted0302 clinical medicineImage Processing Computer-Assisted0202 electrical engineering electronic engineering information engineeringmedicineHumansSegmentationRadiation treatment planningSplit-and-merge segmentationSettore ING-INF/05 - Sistemi Di Elaborazione Delle InformazioniMRgFUS treatmentsInterventionalLeiomyomaMulti-seed adaptive region growingbusiness.industrymedicine.diseaseMagnetic Resonance Imagingfemale genital diseases and pregnancy complicationsComputer Science ApplicationsAutomatic segmentation MRgFUS treatments Multi-seed adaptive region growing Split-and-merge segmentation Uterine fibroids Algorithms Female High-Intensity Focused Ultrasound Ablation Humans Leiomyoma Magnetic Resonance Imaging Magnetic Resonance Imaging Interventional Image Processing Computer-AssistedMRgFUS treatmentRegion growingAutomatic segmentation; MRgFUS treatments; Multi-seed adaptive region growing; Split-and-merge segmentation; Uterine fibroids; Algorithms; Female; High-Intensity Focused Ultrasound Ablation; Humans; Leiomyoma; Magnetic Resonance Imaging; Magnetic Resonance Imaging Interventional; Image Processing Computer-AssistedHigh-Intensity Focused Ultrasound AblationFemale020201 artificial intelligence & image processingAutomatic segmentationbusinessMerge (version control)AlgorithmAlgorithmsUterine fibroidsMedical & Biological Engineering & Computing
researchProduct

Long Non Coding RNA H19: A New Player in Hypoxia-Induced Multiple Myeloma Cell Dissemination

2019

The long non-coding RNA H19 (lncH19) is broadly transcribed in the first stage of development and silenced in most cells of an adult organism

Stromal cellCellHIF-1αBiologyModels BiologicalCatalysisArticleInorganic Chemistrylcsh:ChemistryChemokine receptorWestern blotSettore BIO/13 - Biologia ApplicataCell Line TumormedicineCell AdhesionGene silencingHumansHIF-1 alfaPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5Spectroscopymedicine.diagnostic_testCell growthhypoxiaOrganic ChemistryGeneral MedicineHypoxia (medical)Hypoxia-Inducible Factor 1 alpha Subunitfemale genital diseases and pregnancy complicationsComputer Science ApplicationsCell biologyGene Expression Regulation Neoplasticmultiple myelomamedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Cell cultureembryonic structuresRNA Long Noncodingmedicine.symptomStromal Cellslong non-coding RNA H19 (lncH19)International Journal of Molecular Sciences
researchProduct

The Artificial Kidney Initiation in Kidney Injury 2 (AKIKI2): study protocol for a randomized controlled trial

2019

Abstract Background The Artificial Kidney Initiation in Kidney Injury (AKIKI) trial showed that a delayed renal replacement therapy (RRT) strategy for severe acute kidney injury (AKI) in critically ill patients was safe and associated with major reduction in RRT initiation compared with an early strategy. The five criteria which mandated RRT initiation in the delayed arm were: severe hyperkalemia, severe acidosis, acute pulmonary edema due to fluid overload resulting in severe hypoxemia, serum urea concentration > 40 mmol/l and oliguria/anuria > 72 h. However, duration of anuria/oliguria and level of blood urea are still criteria open to debate. The objective of the study is to compar…

Time FactorsHyperkalemiamedicine.medical_treatment[SDV]Life Sciences [q-bio]Medicine (miscellaneous)030204 cardiovascular system & hematologyKidneyurologic and male genital diseases[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrologylaw.inventionTime-to-Treatment03 medical and health sciencesStudy Protocol0302 clinical medicineRandomized controlled triallawOliguriamedicineHumansMulticenter Studies as TopicPharmacology (medical)030212 general & internal medicineRenal replacement therapyProspective StudiesTreatment outcomeRandomized Controlled Trials as TopicMechanical ventilationlcsh:R5-920business.industryRenal replacement therapyAcute kidney injuryRecovery of FunctionInterim analysismedicine.diseasefemale genital diseases and pregnancy complications3. Good healthAcute kidney injuryCritical careAnesthesiaAnuria[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFrancemedicine.symptombusinesslcsh:Medicine (General)Kidneys Artificial
researchProduct